1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Erythromycin Capsules

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>ERYC Capsules, E-Mycin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Family:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Intended Use:</td>
<td>Pharmaceutical product used as antibiotic agent</td>
</tr>
</tbody>
</table>

2. HAZARDS IDENTIFICATION

Appearance: Orange and White Capsules
Signal Word: DANGER

Statement of Hazard: May cause allergic or asthmatic symptoms or breathing difficulties if inhaled. May cause allergic skin reaction.

Additional Hazard Information:
- **Short Term:** Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted.
- **Long Term:** Animal studies indicate that this material may cause adverse effects on the liver, the developing fetus.

Known Clinical Effects: Ingestion of this material may cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain. Clinical use of this drug has caused liver effects, effects on hearing, skin rash and gastrointestinal disturbances. Serious allergic reactions, including anaphylaxis, have been reported. While this compound causes birth defects in animal studies, experience in humans has not shown increased birth defects in infants born to mothers treated with this compound during pregnancy.

EU Indication of danger: Harmful

EU Hazard Symbols:

EU Risk Phrases: R42/43 - May cause sensitization by inhalation and skin contact.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erythromycin</td>
<td>114-07-8</td>
<td>204-040-1</td>
<td>Xn;R42/43</td>
<td>250 mg***</td>
</tr>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Povidone</td>
<td>9003-38-8</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>FD&amp;C Yellow No. 6; (Sunset yellow)</td>
<td>2783-94-0</td>
<td>220-491-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary
*** per tablet/capsule/lozenge/suppository
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Remove contaminated clothing and wash exposed area with soap and water. Obtain medical assistance if irritation occurs. Delayed effects may occur. For information on potential delayed effects, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon, nitrogen

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable
6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Erythromycin Pfizer OEL TWA-8 Hr: 100 µg/m³


Engineering Controls: Local and general ventilation should be used as necessary, when handling this material in bulk. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
</tr>
<tr>
<td>Color:</td>
<td>White and Orange</td>
</tr>
<tr>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>
10. STABILITY AND REACTIVITY

Stability: Stable at normal conditions
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.
Polymerization: Will not occur

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Erythromycin
Rat Oral LD 50 9272 mg/kg
Mouse Oral LD 50 2929 mg/kg
Mouse Intravenous LD 50 426 mg/kg

Lactose
Rat Oral LD50 > 10 g/kg

FD&C Yellow No. 6; (Sunset yellow)
Rat Oral LD50 > 10,000 mg/kg
Mouse Oral LD50 > 6,000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Erythromycin
Embryo / Fetal Development Rat Oral 6000 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Rat Subcutaneous 50 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Mouse Oral 12,000 mg/kg LOAEL Teratogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Povidone
IARC: Group 3

FD&C Yellow No. 6; (Sunset yellow)
IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: Xn
EU Indication of danger: Harmful

EU Risk Phrases: R42/43 - May cause sensitization by inhalation and skin contact.

EU Safety Phrases: S22 - Do not breathe dust.
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.

OSHA Label:
DANGER
May cause allergic or asthmatic symptoms or breathing difficulties if inhaled.
May cause allergic skin reaction.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision A

Erythromycin
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List: 204-040-1

Lactose
Inventory - United States TSCA - Sect. 8(b): Present
16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R42/43 - May cause sensitization by inhalation and skin contact.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: New data sheet.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet